Last reviewed 2026-04-20 · How we verify

PIRLIMYCIN

FDA-approved active Small molecule Quality 0/100

PIRLIMYCIN is a drug. It is currently FDA-approved.

At a glance

Generic name	PIRLIMYCIN
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PIRLIMYCIN CI brief — competitive landscape report
PIRLIMYCIN updates RSS · CI watch RSS

Frequently asked questions about PIRLIMYCIN

What is PIRLIMYCIN?

PIRLIMYCIN is a Small molecule drug.

What development phase is PIRLIMYCIN in?

PIRLIMYCIN is FDA-approved (marketed).

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing